Item 7.01. Regulation FD Disclosure

     Repros Therapeutics Inc. (the “Company”) announced today that it will host an analyst meeting for the financial community beginning at 10:00 a.m. Eastern Time on Thursday, July 24, 2008 in New York City. The event, which is by invitation only, will focus on the Company’s clinical drug candidate Proellex^®. There will be a live video webcast of the event, and it will be subsequently archived for at least one month on the Company’s website.

     A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

Item 9.01. Financial Statements and Exhibits

     d. Exhibit

Exhibit
Number		Description
99.1		Press Release dated July 14, 2008.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Repros Therapeutics Inc.
Date: July 14, 2008
		By:		/s/ Louis Ploth, Jr.
				Louis Ploth, Jr.
				Vice President, Business Development and
				Chief Financial Officer

EXHIBIT INDEX

Exhibit
Number		Description
99.1		Press Release dated July 14, 2008.